A Clinical Trial of TQ05105 Tablets Combined With TQB3617 Capsules in the Treatment of Myelofibrosis (MF)

Sponsor
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Study ID
NCT06122831
Phase
PHASE1/PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Myelofibrosis

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • TQ05105 Tablets — DRUG
    TQ05105 Tablets is a Janus kinase 1 (JAK1) and Janus kinase 2 (JAK2) Inhibitor.
  • TQB3617 Capsules — DRUG
    TQB3617 Capsules is a Bromodomain and Extra-Terminal (BET) Inhibitor

Study Details

This is an open, single-arm, multi-center clinical study designed to evaluate the efficacy and safety of TQ05105 Tablets combined with TQB3617 Capsules in patients with intermediate- and high-risk Myelofibrosis.

Key Dates

First listed
Nov 8, 2023
Start date
Dec 12, 2023
Status verified
Dec 2025
Primary completion
Dec 31, 2026
Completion
Apr 30, 2027

Study Design

Enrollment
92 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: TQ05105 Tablets + TQB3617 Capsules
    TQ05105 Tablets combined with TQB3617 Capsules, orally administered. 21 days as a treatment cycle. TQB3617 Capsules, orally administered, 21 days as a treatment cycle.

Primary Outcome Measure

Maximal tolerance dose (MTD) [ Time Frame: Up to 2 years. ]

Central Contacts

Related Studies